ASML to 2035 still has a rare long-term strategic franchise, but the long-range stock outlook should be framed with explicit revenue, margin, and valuation assumptions rather than pure enthusiasm.

ASML to 2030 still has one of the clearest strategic runways in European technology, but long-term targets should be anchored in official demand and margin signals rather than pure AI enthusiasm.

Eli Lilly still has a credible path to a materially larger business by 2030, but the stock is no longer cheap enough for optimism alone. The central question is whether obesity, diabetes, and pipeline ...

DAX 40 outlook with quantified scenarios, earnings and valuation context, macro triggers, and institutional views for 2027.

The decade thesis is that DAX remains Europe's premier industrial and software beta. A decade from now, the most important question is whether Germany emer ...

The bearish case for copper is credible only when the current data stop looking noisy and start looking directional. This article focuses on the measurable conditions that would justify a deeper ...

Ever juggled work emails, personal shopping, and family streaming on the same browser? 😩 Microsoft Edge multiple profiles solve that chaos, letting you keep everything organized while Edge profiles ...

Why Ethereum could fall next, with verified macro and market-structure risks, downside triggers, and review checkpoints.

AstraZeneca does not need a broken business to fall from $184.96. It only needs the market to decide that a stock trading near 28.0x trailing reported earnings and about 20.2x trailing core earnings ...

Microsoft stock analysis with current valuation, earnings, AI exposure, macro context, and scenario-based ranges backed by current sources.

S&P 500 with valuation, earnings, inflation, scenario probabilities, trigger levels, and institutional data updated for mid-2026.

Why Sensex could keep rising, with measurable catalysts, valuation context, institutional views, and scenario-based positioning.